SEC EDGARAUG 251 min read$COR

Campbell Elizabeth S sold $3.7M of COR

Campbell Elizabeth S (Executive Vice President) sold 11,300 shares of Cencora, Inc. (COR) at $324.12 ($3.66M total) on 2026-08-24.

Original reporting

SEC EDGAR · Campbell Elizabeth S

Published Aug 25, 2026, 8:14 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 25, 2026, 8:21 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$COR

Bearish

medium confidence

Mentioned

$COR

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CORBearishLow

Why it matters

The insider sell is material for short‑term traders monitoring insider activity.

Market read

Provides fresh insider‑sell data for COR, useful for short‑term positioning.

What to watch

No pre‑arranged 10b5‑1 plan; the sale may be driven by personal liquidity needs.

Relevance 6/10Novelty 7/10Timing: post‑market 2026‑08‑24

Background

Form 4 filings disclose insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CORBearishMedium confidence

Context

Executive Vice President sold 11,300 shares for $3.66M, reducing her stake to 19,455 shares.

Expected impact

Potential short-term downward pressure on COR stock.

Evidence & confidence

A $3.6M sale by an EVP is material for a mid‑cap stock and is the first public disclosure of the transaction.

Market effects

Sector

Minimal impact on the pharmaceutical distribution sector beyond the specific insider activity.

Regional

Limited to U.S. markets where COR trades.

Global

Low global relevance; primarily of interest to investors in COR.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

Executive
Campbell Elizabeth S
Executive Vice President of Cencora, Inc.

Read at source ← All news

SEP 10

$CORHighAI 8/10

Is Cencora Stock Underperforming the Dow?

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

yahoo.com2 min

SEP 8

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

yahoo.com3 min

SEP 6

$CORHighAI 8/10

Why Cencora (COR) Is Getting Attention Today

Cencora (COR) reported Q3 2026 adjusted EPS of $4.48, beating estimates, and raised full-year guidance. Shares fell 1.86% to $330.95 but gained 20.75% over 90 days. The company's long-term returns are strong, with a 1-year return of 14.01% and a 5-year return of 183.23%. Analysts suggest fair value at $372.58, citing digital investments and healthcare trends.

simplywall.st2 min

AUG 23

$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

aol.com3 min

AUG 21

$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

nai500.com3 min

AUG 20

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

finance.yahoo.com3 min